David J. Franklin
Corporate Officer/Principal bij Intarcia Therapeutics, Inc.
Profiel
David J.
Franklin is currently the Vice President-Alliance Management & Advocacy at Intarcia Therapeutics, Inc. He previously worked as a Senior Vice President-Global Marketing at Idenix Pharmaceuticals LLC from 1998 to 2006 and as a Product Manager at Bristol Myers Squibb Co. from 1990 to 1995.
Mr. Franklin received his undergraduate degree from Gettysburg College in 1988.
Actieve functies van David J. Franklin
Bedrijven | Functie | Begin |
---|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01-03-2006 |
Eerdere bekende functies van David J. Franklin
Bedrijven | Functie | Einde |
---|---|---|
IDENIX PHARMACEUTICALS INC | Verkoop & Marketing | 30-03-2006 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-01-1995 |
Opleiding van David J. Franklin
Gettysburg College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Idenix Pharmaceuticals LLC
Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |